Generalizability of HFrEF trials 41 Supplementary table 1 (continued). Characteristics, inclusion and exclusion criteria of trials Study name BEAUTIFUL CONFIRM-HF FAIR-HF PANTHEON SHIFT Any serious disease likely to interfere with the conduct of the study Patient for whom life expectancy is shorter than the study duration for a non-cardiovascular illness (e.g. cancer) Known active bacterial infection. Clinical evidence of current malignancy with exception of basal cell or squamous cell carcinoma of the skin, and cervical intraepithelial neoplasia. Currently receiving systemic chemotherapy and/or radiotherapy. Known active infection, CRP > 20 mg/L, clinically significant bleeding, active malignancy Any condition or therapy, which would make the patient unsuitable for the study, or life expectancy less than 12 months (e.g., active malignancy) Any serious disease likely to interfere with the conduct of the study or any non-cardiac disease (e.g., cancer) judged likely to limit 3-years survival Known carriers of HIV antibodies Subjects with known seropositivity to HIV Known HIV/AIDS. Known carriers of HIV antibodies Requirement of any of the following 48 hours prior to randomization:- Intravenous vasodilating drugs (e.g., nitrates, nitroprusside), IV natriuretic peptides (e.g., nesiritide, carperitide), IV positive inotropic agents, IV diuretics, IV antibiotics,mechanical support (e.g., intra-aortic balloon pump, endotrachealintubation, mechanical ventilation, or any ventricular assist device) 2.1
RkJQdWJsaXNoZXIy MjY0ODMw